key: cord-0259300-5uett4kk
authors: Feng, Y.; Chen, J.; Yao, T.; Chang, Y.; Li, X.; Xing, R.; Li, H.; Xie, R.; Zhang, X.; Wei, Z.; Mu, S.; Liu, L.; Feng, L.; Wang, S.
title: Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine in High-Risk Occupational Population: a randomized, parallel, controlled clinical trial
date: 2021-08-09
journal: nan
DOI: 10.1101/2021.08.06.21261696
sha: 25af1f7855a15e25f9008aee44236093783c607c
doc_id: 259300
cord_uid: 5uett4kk

Vaccination is urgently needed to prevent the global spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here, we conducted a randomized, parallel, controlled clinical trial for assessment of the immunogenicity and safety of an inactivated SARS-CoV-2 vaccine, aiming to determine an appropriate vaccination interval for high-risk occupational population. Participants were randomly assigned to receive two doses of inactivated SARS-CoV-2 vaccine at an interval of either 14 days, 21 days or 28 days. The primary immunogenicity endpoints were neutralization antibody seroconversion and geometric mean titer (GMT) at 28 days after the second dose. Our results showed that the seroconversion rates (GMT [≥] 16) were all 100% in the three groups and the 0-21 and 0-28 groups elicited significantly higher SARS-CoV-2 neutralizing antibody level. All reported adverse reactions were mild. (Chinese Clinical Trial Registry: ChiCTR2100041705, ChiCTR2100041706)

The ongoing pandemic of coronavirus disease 2019 (COVID-19) induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to an unprecedented global public health crisis. Globally, as of August 4, 2021, more than 199 million cases of SARS-CoV-2 infection and more than 4.2 million deaths have been reported 1 . SARS-CoV-2 belongs to the Betacoronavirus of the family Coronaviridae, and commonly induces a spectrum of clinical manifestations ranging from asymptomatic, minor flu-like symptoms to acute respiratory distress syndrome (ARDS), pneumonia and even death 2 . Compared with other coronaviruses, SARS-CoV-2 appears to undergo more rapid transmission and variation 3, 4 . Although it is proved to be effective that the COVID-19 pandemic can be controlled using strict social hygiene measures such as physical distancing and masks, the absence of herd immunity leaving people susceptible to further waves of SARS-CoV-2 infection, especially for the high-risk occupational population. Meantime, the measures taken to contain SARS-CoV-2 have placed a substantial burden on health-care systems around the world, with far-reaching social and economic consequences. Hence, a safe and effective vaccine against COVID-19 is urgently needed to prevent the resurgence of the epidemic.

Many countries have accelerated the process of clinical trials to determine an effective and safe vaccine to prevent COVID-19 pandemic. Currently, more than 292 candidate vaccines are in development worldwide, 37 of which are already in phase 3 trials using different platforms 5 , including nucleic acid (DNA and RNA) vaccines, viral vector (replicating and non-replicating) vaccines, virus-like particles vaccines, peptide-based vaccines, recombinant protein vaccines and inactivated vaccines [6] [7] [8] .

Inactivated vaccines have been widely used against various infectious diseases for decades. Their long history of use confers some advantages, such as well-developed and mature manufacturing processes, ease of scaling up production and storage, and the ability to present multiple viral proteins for immune recognition. In addition, inactivated vaccines induce high levels of neutralizing antibody titers in mice, rats, guinea pigs, rabbits, and nonhuman primates to provide protection against SARS-CoV-2 [9] [10] [11] . Moreover, the results of previous clinical trials on the inactivated vaccines conducted in several countries showed good neutralizing antibody responses and/or efficacy against disease caused by COVID-19 [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] Previous studies [15] [16] [17] [22] [23] [24] have shown that the three immunization programs (0, 14 procedure, 0, 21 procedure or 0, 28 procedure) induce varying degrees of immune effect, but the optimal interval of injections remains unclear. Furthermore, the safety and immunogenicity of inactivated SARS-CoV-2 vaccine in occupational high-risk . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted August 9, 2021. ; https://doi.org/10.1101/2021.08.06.21261696 doi: medRxiv preprint population have not been reported. Therefore, based on the preliminary clinical trials, we explored the immunogenicity and safety of the three different SARS-CoV-2 inactivated vaccination schemes at an interval of either 14 days, 21 days or 28 days in high-risk occupational population to optimize the inactivated vaccination regimen. We would continue to follow up until months 3, 6, and 12 in the further study.

We conducted a randomized, controlled clinical trial of the SARS-CoV-2 inactivated vaccine manufactured by Beijing Biological Products Institute Co., Ltd. in Taiyuan CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted August 9, 2021. ; https://doi.org/10.1101/2021.08.06.21261696 doi: medRxiv preprint form after being informed about the study. The trial was registered with ChiCTR.org.cn (ChiCTR2100041705, ChiCTR2100041706).

A computerized random number generator performed block randomization with a randomly selected block size of 6, and eligible participants were randomly assigned into three groups to receive two doses inactivated COVID-19 vaccine at the schedule of day 0-14, day 0-21, or day 0-28. Each dose of vaccine containing 4 µg of inactivated SARS-CoV-2 virus antigen was intramuscularly injected into the lateral deltoid muscle of the upper arm. The vaccines used in this study were inactivated vaccine (Vero Cell) produced by Beijing Biological Products Institute Co., Ltd.

Demographic information (age, gender, body mass index (BMI), marital status, and education level), influenza vaccination history, smoking, drinking, and chronic diseases were collected via questionnaire investigation.

After each dose was vaccinated, the participants were observed for any immediate reaction for 30 min, and local and systemic adverse reactions were collected. Participants were required to record the local adverse events and systemic adverse events on diary cards within 7 days of each injection. Any other unsolicited symptoms were also recorded during a 28-day follow-up period after each injection by spontaneous report from the participants combined with the regular visit. The solicited adverse reactions included local reactions (pain, induration, swelling, rash, flush, and pruritus) and systematic reactions (fever, diarrhea, dysphagia, anorexia, vomiting, nausea, muscle pain (non-vaccination sites), arthralgia, headache, cough, dyspnea, skin and mucosal abnormalities, acute allergic reactions, and fatigue).

Oropharyngeal/nasal swabs were collected for detecting SARS-CoV-2 nucleic . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted August 9, 2021. ; https://doi.org/10.1101/2021.08.06.21261696 doi: medRxiv preprint acid from all subjects by using reverse transcriptase-polymerase chain reaction (RT-PCR) test before the first dose of vaccine vaccination, before the second dose of vaccine vaccination, 28 days after the whole course of vaccination, respectively.

Blood samples were taken from participants for serology tests before the first injection and on day 28 after the second injection. The neutralizing antibody to live SARS-CoV-2 (strain 19nCoV-CDC-Tan-Strain 05 [QD01]) were quantified using a micro cytopathogenic effect assay at baseline and 28 days after immunization. We defined the neutralizing antibody seroconversion rate as post-injection titer of a 16-fold. (Baseline titers were all below 1:4).

The primary immunogenic endpoints were the seroconversion rates (geometric mean titer (GMT) 

The study sample size of 360 participants provided 84.4% power to detect a difference of 5% (85% vs. 80%) of responders in the 0-21 and 0-28 vaccination groups compared with the 0-14 group, respectively in airport ground staff and public security officers. Data were recorded using EpiData, and analyses were performed using SAS version 9.3 (SAS Institute, Cary, NC, USA). Analysis of variance (ANOVA) was used to analyze continuous data, and the chi-square or Fisher's exact test was used for categorical data. We assessed immunogenic endpoints by the modified intention-to-treat (ITT) analysis (ie, subjects who undertake randomization)

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 9, 2021. ; https://doi.org/10.1101/2021.08.06.21261696 doi: medRxiv preprint and per-protocol (PP) analysis (ie, subjects who compliant to the protocol, receive 2 doses of vaccine according to the requirements of the protocol, and have serum-testing results before and after immunization). Multinomial logistic regression analysis and unconditional logistic regression model was used to determine the influencing factors of SARS-CoV-2 neutralizing antibody immunization. The safety analysis was performed on data from all subjects who received vaccination after randomization. The level of statistical significance for all analyses was P < 0.05.

Between January and May 2021, 810 participants were screened, and 809 were enrolled (73.18% male, 26.82% female; mean age 38.78 years). Of the 809 participants who were enrolled, 405 participants were the public security officers and 404 participants were the airport ground staff. 270 participants were included in the Table 1 . There were no significant differences in demographic and behavioral characteristics among the three groups at baseline and 28 days after the whole course of vaccination (P > 0.05; Table   1 , Supplement 1).

The seroconversion rate and GMT of SARS-CoV-2 neutralizing antibody in the three groups . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 9, 2021. Table 2 ). The positive rates of neutralizing antibody (GMT ≥ 32, 64, 128, or 256) in the 0-21 and 0-28 groups were significantly higher than that in the 0-14 group, and there was no significant difference between the 0-21 group and 0-28 group. The modified ITT analysis yielded similar results ( Table 2) .

In the 0-14 group, the proportion of neutralizing antibody was higher at the GMT 32-63 (25.78%, 66/256) and 64-127 (29.30%, 75/256), while the proportion of neutralizing antibody in the 0-21 and 0-28 groups was higher at the GMT of 64-127 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 9, 2021. ; (Table 3) .

Neutralizing Antibody Immunization . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (Table 4 ).

The overall incidence of adverse reactions was 11 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 9, 2021. ;

None of the subjects reported serious adverse reactions or became SARS-CoV-2 infected during the follow-up period (Table 5 ). is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 9, 2021. ; https://doi.org/10.1101/2021.08.06.21261696 doi: medRxiv preprint good immune effect.

In our research, the SARS-CoV-2 neutralizing antibody titers of the 0-28, 0-21 groups were significantly greater than that of 0-14 group. Some trials have also designed to compare the immunogenicity of inactivated SARS-CoV-2 vaccination regimens in healthy adults [15] [16] [17] 22 . Xia 15, 16 Similarly, other mRNA vaccine and vector-based vaccine in phase 3 trial 18, 21 also elicited a better immunogenicity at an interval of 0-21 days, with the presence of neutralizing antibody in more than 90% of the participants. In our study, the neutralizing antibody titer in 0-21 group was numerically higher than that of 0-28 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 9, 2021. ; 1 3 group. The current studies have indicated that an interval of both 0-21 and 0-28 days elicited significantly higher SARS-CoV-2 neutralizing antibody levels than 0-14 days interval, with a numerically higher neutralizing antibody level in 0-21 days interval, suggesting that the 0-21 days interval schedule of the SARS-CoV-2 vaccines may be a better regimen.

The incidence of adverse reactions in the 0-14, 0-21 and 0-28 groups were similarly low. Moreover, we did not find severe adverse reaction, with the most common symptom being injection-site pain, indicating no safety concerns. The overall incidence of adverse events after vaccination was 3.72-4.81% in our vaccine-treated groups, which is noticeably lower than that of other SARS-CoV-2

vaccine platform candidates such as viral-vectored vaccines, DNA or RNA vaccines [26] [27] [28] [29] [30] [31] . The safety profile of this vaccine in our study is also lower than that of other inactivated SARS-CoV-2 vaccines 15, 17 , which may be related to different population characteristics, and minor adverse reactions that are not reported.

Our study had several limitations. First, we only reported immune response data for the high-risk occupational population aged 18 to 59 years. Further studies are required to assess the immunogenicity of inactivated SARS-CoV-2 vaccine in various populations, including general population, older people, children and adolescents.

Second, data on long-term immunogenicity is not yet available, and the ongoing trial will provide more information. Third, cellular immunity and immune memory were not measured in the current study which need to be further studied.

In summary, a two-dose of inactivated SARS-CoV-2 vaccine at 0-21 days and 0-28 days regimens significantly improved SARS-CoV-2 neutralizing antibody level compared to the 0-14 days regimen in high-risk occupational population. And the neutralizing antibody titer in 0-21 group was numerically higher than that in 0-28 group.

The full study protocol and the datasets, which includes all data fields reported in this study, are available, following manuscript publication, upon request from the . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 9, 2021. ; 

All authors have seen and approved the manuscript, contributed significantly to the work. There are no known competing interests involved in this publication.

The study was supported by the COVID-19 Project of Shanxi Provincial Finance, and the Project of Shanxi Provincial Key Laboratory for major infectious disease response.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 9, 2021. ; Results expressed as n (%); a Fisher's exact test.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 9, 2021. ; https://doi.org/10.1101/2021.08.06.21261696 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 9, 2021. GMT, geometric mean titer; CI, confidence interval; a b There was significant difference with the different letters.

.

It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 9, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 9, 2021. ; https://doi.org/10.1101/2021.08.06.21261696 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted August 9, 2021. ; https://doi.org/10.1101/2021.08.06.21261696 doi: medRxiv preprint Results expressed as n (%); * Adverse reaction data only list the occurrence of this symptom.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted August 9, 2021. ; https://doi.org/10.1101/2021.08.06.21261696 doi: medRxiv preprint * Lost to follow up including not being at the study site, or illness. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted August 9, 2021. ;

World Health Organization. WHO Coronavirus (COVID-19) Dashboard

A Review of the Progress and Challenges of Developing a Vaccine for COVID-19

A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Draft landscape and tracker of COVID-19 candidate vaccines. World Health Organization

A Comprehensive Review of COVID-19 Virology, Vaccines, Variants, and Therapeutics. Current medical science

The COVID-19 vaccine development landscape

SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates

Development of an inactivated vaccine candidate for SARS-CoV-2

Low toxicity and high immunogenicity of an inactivated vaccine candidate against COVID-19 in different animal models. Emerging microbes & infections 9

Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. The Lancet Infectious diseases 21

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. The Lancet Infectious diseases 21

COVID-19: Coronavirus Vaccine Development Updates

Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. The Lancet Infectious diseases 19

Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial

Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

Immunogenicity and safety of a severe acute respiratory syndrome coronavirus 2 inactivated vaccine in healthy adults: randomized, double-blind, and placebo-controlled phase 1 and phase 2 clinical trials

Randomized, double-blinded and placebo-controlled phase II trial of an inactivated SARS-CoV-2 vaccine in healthy adults. Clinical infectious diseases. Online ahead of print

The safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in Chinese adults aged 18-59 years: A phase I randomized, double-blinded, controlled trial

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against

-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

An mRNA Vaccine against SARS-CoV-2 -Preliminary Report

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5

COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults